Using computer simulations, University of Oregon researchers find that knowing all possible mutations isn't enough to predict where a protein will go
University of Oregon scientists theorized that they could manipulate a protein one mutation at a time and predict its evolution. They sought to prove it. And failed.
Researchers in the University of Oregon lab of Michael Harms predicted the evolutionary paths of different simulated proteins. The points in the image are protein sequences. The edges denote probabilities of trajectories. Colors denote low to high fitness (purple to yellow) or falsely inaccessible or falsely accessible routes (red and blue).
Illustration by Michael Harms and Zach Sailer
They do think, however, that they've found a fundamental truth underlying unpredictability in a biological system. Basic physical limitations make uncertainty the norm, they reported in a paper published online Oct. 23 in the Proceedings of the National Academy of Sciences.
"While we got a surprising negative result, we were able to say why," said Michael J. Harms, a professor in the UO Department of Chemistry and Biochemistry and scientist in the Institute of Molecular Biology. "That is a positive. Our simple study provides confirmation of what many people in the field have observed repeatedly -- unpredictability. It appears it is universal."
The research was a digital affair, done with computer simulations designed by UO doctoral student Zachary R. Sailer. He and Harms created a simple lattice protein, using an approach previously created in the Harms lab, with a random sequence of 12 amino acids. They then ran evolutionary simulations to optimize stability, a physical property of the protein.
The goal was to use the effects of all 228 mutations known to be associated with the starting protein to predict these simulated trajectories: which mutation would occur, when, over time. The ability to project ahead faded fast after the first two mutations. After that, the anticipated trajectories went astray amid a growing number of rerouting probabilities.
"The quality of your information actually decays over time," Sailer said. "As mutations accumulate, the effects of the mutations that you measured start to change so that you can't predict where you are going."
In their paper, Sailer and Harms suggest that physics, particularly thermodynamics, is at play. Each mutation alters the protein in a small, but nonlinear way. This means that the effect of each mutation depends on all mutations that occurred before.
"I think that what we showed, fundamentally, is that even if you know a lot about a system, about a protein, you cannot predict how it evolves because of the physics of the system," Harms said. "There are physical rules that limit evolution and its predictability."
How proteins evolve is a fundamental question in evolutionary biology, from both a philosophical perspective, to learn more about the machinery of biological systems, and for clues that might lead to improved or better drugs.
"Practically," Harms said, "our research may help us learn how to prevent the evolution of antibiotic resistance in bacteria." Almost all bacterial borne infections are developing resistance to antibiotics, creating a leading public health concern around the world.
"Rather than studying the effects of all individual mutations," Sailer added, "maybe we should study random combinations of many mutations. Such an approach might help us predict the evolution of resistance."
Work is underway in the Harms lab to test for this possibility on real proteins. "We're building computational tools that let us analyze antibiotic resistance datasets, and we are getting hints that a combinatorial approach does work," Harms said. "It's more complicated than studying individual mutations, but our work shows the individual approach is unlikely to work."
A fellowship to Harms from the Alfred P. Sloan Foundation funded the research. The UO also provided additional research funds to Sailer.
Sources: Michael J. Harms, assistant professor, Department of Chemistry and Biochemistry and Institute of Molecular Biology, 541-346-9002, firstname.lastname@example.org, and Zachary R. Sailer, doctoral student, Department of Chemistry and Biochemistry and Institute of Molecular Biology, 541-346-9003, email@example.com
Note: The UO is equipped with an on-campus television studio with a point-of-origin Vyvx connection, which provides broadcast-quality video to networks worldwide via fiber optic network. There also is video access to satellite uplink and audio access to an ISDN codec for broadcast-quality radio interviews.
About Michael Harms: http://molbio.
Harm's Lab: https:/
Institute of Molecular Biology: http://molbio.
Department of Chemistry and Biochemistry: https:/
Jim Barlow | EurekAlert!
Gut microbiome regulates the intestinal immune system, researchers find
19.12.2018 | Brown University
Greener days ahead for carbon fuels
19.12.2018 | DOE/Lawrence Berkeley National Laboratory
Different eras of civilization are defined by the discovery of new materials, as new materials drive new capabilities. And yet, identifying the best material...
Researchers from the University of Basel have reported a new method that allows the physical state of just a few atoms or molecules within a network to be controlled. It is based on the spontaneous self-organization of molecules into extensive networks with pores about one nanometer in size. In the journal ‘small’, the physicists reported on their investigations, which could be of particular importance for the development of new storage devices.
Around the world, researchers are attempting to shrink data storage devices to achieve as large a storage capacity in as small a space as possible. In almost...
The more objects we make "smart," from watches to entire buildings, the greater the need for these devices to store and retrieve massive amounts of data quickly without consuming too much power.
Millions of new memory cells could be part of a computer chip and provide that speed and energy savings, thanks to the discovery of a previously unobserved...
What if, instead of turning up the thermostat, you could warm up with high-tech, flexible patches sewn into your clothes - while significantly reducing your...
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth – this was discovered by researchers from the University of Basel’s Biozentrum two years ago. In a follow-up study, recently published in “Cell Reports”, the scientists report that this drug cocktail induces cancer cell death by switching off their energy supply.
The widely used anti-diabetes drug metformin not only reduces blood sugar but also has an anti-cancer effect. However, the metformin dose commonly used in the...
12.12.2018 | Event News
10.12.2018 | Event News
06.12.2018 | Event News
19.12.2018 | Materials Sciences
19.12.2018 | Materials Sciences
19.12.2018 | Life Sciences